Changes in Components of Metabolic Syndrome after Antiviral Eradication in Hepatitis C Virus Infection

• Published in: Life (Basel, Switzerland) Vol. 13; no. 2; p. 534
• Main Authors: Trifan, Anca, Cuciureanu, Tudor, Nastasa, Robert, Stratina, Ermina, Zenovia, Sebastian, Muzica, Cristina Maria, Huiban, Laura, Singeap, Ana-Maria, Chiriac, Stefan, Sfarti, Catalin, Cojocariu, Camelia, Girleanu, Irina, Minea, Horia, Stafie, Remus, Rotaru, Adrian, Stanciu, Carol
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-02-2023; MDPI
• Subjects: Antiviral agents; Biopsy; Blood pressure; Body mass index; Cardiovascular diseases; Care and treatment; Cholesterol; chronic hepatitis C infection; Chronic infection; Cirrhosis; Complications and side effects; Diabetes; Diagnosis; direct-acting antivirals therapy; Eradication; Evaluation; Glucose; Health risks; Health services; Hemoglobin; Hepatitis; Hepatitis C; Hepatitis C virus; Infections; Interferon; Laboratories; Lipids; Liver cancer; Liver cirrhosis; Liver diseases; Low density lipoprotein; metabolic changes; Metabolic disorders; Metabolic syndrome; Metabolic syndrome X; Obesity; Overweight; Patient outcomes; Patients; Population studies; Risk factors; Statistical analysis; SVR12; Triglycerides; Viruses; Weight; Womens health; Romania; metabolic changes; SVR12; direct-acting antivirals therapy; chronic hepatitis C infection
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life13020534

Chronic hepatitis C infection is a systemic disease that affects over 71 million patients all over the world and it is to be considered nowadays as a new cardiometabolic risk factor. This study aimed to evaluate the weight and metabolic changes after viral eradication in patients with hepatitis C virus (HCV) infection. We conducted a prospective study between October 2017 to December 2021, in a tertiary care center, in which we included 132 patients with HCV or cirrhosis. All patients received treatment with direct antivirals (DAAs) and achieved sustained viral response at 12 weeks (SVR12). During the study, clinical laboratory data and Fibroscan examinations were recorded in all patients. The study group was evaluated at the initiation of antiviral treatment, at SVR12, and within an average follow-up period of 6 months to 12 months after the previous evaluation. Evaluation at SVR12 and the data recorded in the post-SVR surveillance period show a further increase in BMI compared with baseline measurements with a statistically significant difference (27.11 ± 3.22 vs. 27.415 ± 3.03 vs. 28.04 ± 1.11 kg/m
,
= 0.012). The same observation was noticed for waist circumference (WC) at post-SVR evaluation (87.6 ± 13.1 vs. 88.4 ± 13.6 cm,
= 0.031). Moreover, the study population registered an increase in the average total cholesterol (TC) values at post-SVR evaluation (177.01 ± 42.2 mg/dL,
= 0.014) compared to baseline. In addition, the serum level of triglycerides had been modified after viral clearance, with a minimal decrease in the mean values of triglycerides (TGD) at SVR-12 assessment (133.48 ± 41.8 mg/dL,
= 0.78), followed by a significant increase to the mean value of 145.4 ± 47.2 mg/dL (
= 0.026) in the third evaluation. Our study highlights that HCV eradication does not improve the lipid profile in the short term, and these patients still have an additional cardiovascular risk factor due to high levels of TC, TGD, and weight gain.